|
2025 Journal Article Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trialEmmett, Louise, Papa, Nathan, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M, Sandhu, Shahneen, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ayati, Narjess, Niu, Claire, Hofman, Michael S, Martin, Andrew James, Thomas, Hayley, Davis, Ian D, Stockler, Martin R and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2025). Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (9), 1168-1177. doi: 10.1016/S1470-2045(25)00339-0 |
|
2025 Conference Publication Results from the phase Ib dose escalation of 212Pb-ADVC001 in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC): The theraPb trialHansen, A.R., Pattison, D.A., Gan, C.L., Goh, J.C.H., Ngai, S., Katchel, L., Holmes, I., Baker, S., Campbell, L., Brady, J., Santoro, P., Crumbaker, M., Baronet, M., Rose, S., Adamovich, A.A., Puttick, S., Kryza, T., Kuan, K., Karmann, A. and Wyld, D.K. (2025). Results from the phase Ib dose escalation of 212Pb-ADVC001 in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC): The theraPb trial. ESMO Congress 2025, Berlin, Germany, 17-21 October 2025. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2025.08.3004 |
|
2025 Journal Article A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancerRoberts, Matthew J., Roberts, Natasha A., Pelecanos, Anita, Yaxley, John W., Harley, Simon J. D., Siriwardana, Amila R., Cullen, Karla, Prior, Marita, Lindsay, Karen, Vela, Ian, Kuchel, Anna, Dhiantravan, Nattakorn, Thomas, Paul and Pattison, David A. (2025). A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer. EJNMMI Research, 15 (1) 92, 1-10. doi: 10.1186/s13550-025-01265-z |
|
2025 Conference Publication Phase Ib/IIa dose escalation and expansion study of 212Pb-ADVC001 in metastatic castration-resistant prostate cancer (mCRPC): TheraPb-Phase I/II Trial in ProgressGoh, Jeffrey, Pattison, David, Ngai, Stanley, Katchel, Loren, Holmes, Ingrid, Baker, Sean, Biggs, Heather, Cuscaden, Claire, Campbell, Louise, Brady, Jasmine, Lindsay, Karen, Latter, Melissa, Griffiths, Matthew, O'Mahoney, Eoin, Dhiantravan, Nattakorn, Francis, Roslyn, Rose, Stephen, Soderholm, Amelia, Baronet, Meghan, Crumbaker, Megan, Kryza, Thomas, Shakti, Stelle, Naidoo, Sheruna, Puttick, Simon, Horsfall, Aimee, Barkhausen, Christoph, Kuan, Kevin, Santoro, Paola, Skingley, Lesley ... Hansen, Aaron (2025). Phase Ib/IIa dose escalation and expansion study of 212Pb-ADVC001 in metastatic castration-resistant prostate cancer (mCRPC): TheraPb-Phase I/II Trial in Progress. 2025 ANZUP Annual Scientific Meeting, Sydney, NSW Australia, 20-22 July 2025. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. |
|
2025 Journal Article Peptide receptor radionuclide therapy in malignant insulinomaPattison, David A., Kong, Grace, Akhurst, Timothy, Burge, Matthew, Chiang, Cherie, Hofman, Michael S., Hung, Te-Jui, Love, Amanda, Michael, Michael, Okano, Satomi, Ravi Kumar, Aravind S., Sachithanandan, Nirupa, Wyld, David and Hicks, Rodney J. (2025). Peptide receptor radionuclide therapy in malignant insulinoma. Endocrine-Related Cancer, 32 (6) e250018, 6. doi: 10.1530/erc-25-0018 |
|
2025 Conference Publication Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomized study of cessation of somatostatin analogues (SSA) after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and pancreatic neuroendocrine tumoursBurge, Matthew E., Wyld, David, Pattison, David A., Bahamad, Sandra, Hayes, Sarah J., Kuszewski, Julia A., Chantrill, Lorraine A., Price, Timothy Jay, Wong, Hui-Li, Chan, David, Grover, Piyush, Michael, Michael, Siu, Derrick, Bishop, Christine, Barker, Daniel, Goodwin, Rachel Anne, O'Callaghan, Christopher J., Loree, Jonathan M. and Mak, W. John (2025). Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomized study of cessation of somatostatin analogues (SSA) after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and pancreatic neuroendocrine tumours. 2025 ASCO Annual Meeting, Chicago, IL United States, 30 May - 3 June 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.tps4224 |
|
2025 Journal Article Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trialKwan, Edmond M., Ng, Sarah W. S., Tolmeijer, Sofie H., Emmett, Louise, Sandhu, Shahneen, Buteau, James P., Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Subhash, Vinod, Lee, Sze-Ting, Scott, Andrew M., Martin, Andrew J., Stockler, Martin R., Donnellan, Grainne, Annala, Matti, Herberts, Cameron, Davis, Ian D., Hofman, Michael S., Azad, Arun A., Wyatt, Alexander W., Akhurst, Tim, Alipour, Ramin, Bailey, Dale L., Banks, Patricia, Beaulieu, Alexis, Campbell, Louise, Chua, Wei, Crumbaker, Megan ... on behalf of the TheraP Investigators and the ANZUP Cancer Trials Group (2025). Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. Nature Medicine, 2025 (8), 1-15. doi: 10.1038/s41591-025-03704-9 |
|
2025 Journal Article Biopsy decision for intermediate–high-risk lung nodules is significantly changed when guided by prior positron emission tomography/CT (PET/CT) results: results of the prospective PET-FIRST studyFielding, David, Sidhu, Calvin, Alkhater, Mahmoud, Alawami, Moayed, Kops, Stephan E. P., van der Heijden, Erik H. F. M., Bashirzadeh, Farzad, Windsor, Morgan, Nixon, Elizabeth, Son, Jung Hwa, Ananda Setty, Niranjan, Pattison, David A., Fong, William, Bhatt, Manoj, Dhiantravan, Nattakorn, Ramsay, Stuart, Boots, Robert, Putt, Michael, Pratt, Gary, Bettington, Catherine, Francis, Roslyn, Thomas, Paul, Steinke, Karin and Thomas, Rajesh (2025). Biopsy decision for intermediate–high-risk lung nodules is significantly changed when guided by prior positron emission tomography/CT (PET/CT) results: results of the prospective PET-FIRST study. BMJ Open Respiratory Research, 12 (1) e002553, 1-10. doi: 10.1136/bmjresp-2024-002553 |
|
2025 Journal Article The Utah NeoSeq Project: a collaborative multidisciplinary program to facilitate genomic diagnostics in the neonatal intensive care unitJenkins, Sabrina Malone, Palmquist, Rachel N., Moore, Barry, Boyden, Steven E., Nicholas, Thomas J., Bayrak-Toydemir, Pinar, Mao, Rong, Farrell, J. Andrew R., Holt, Carson H., Rynearson, Shawn G., Solorzano, Chelsea M., Ward, Alistair, Best, D. Hunter, Al-Sweel, Najla, Bentley, Dawn L., Brunelli, Luca, Chow, Clement Y., Close, Devin W., Cormier, Michael J., Deshotel, Malia J., Durtschi, Jacob, Eide, Erik J., Floyd, Luaiva, Fredrickson, Eric K., Fulmer, Makenzie L., Hernandez, Edgar J., Kapron, Ashley L., Karren, Mary Anne, Lewis, Robert G. ... Bonkowsky, Joshua L. (2025). The Utah NeoSeq Project: a collaborative multidisciplinary program to facilitate genomic diagnostics in the neonatal intensive care unit. Npj Genomic Medicine, 10 (1) 26. doi: 10.1038/s41525-025-00483-7 |
|
2025 Journal Article Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialEmmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony M, Sandhu, Shahneen, Nguyen, Andrew, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Kumar, Aravind S Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia, Butler, Patrick ... Bills, Madison (2025). Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (3), 291-299. doi: 10.1016/s1470-2045(25)00009-9 |
|
2025 Conference Publication Phase Ib/IIa dose escalation and expansion study of [ 212 Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: TheraPb–phase I/II studyHansen, Aaron Richard, Pattison, David A., Ngai, Stanley, Karmann, Anna, Walker, Amanda J., Campbell, Louise, Brady, Jasmine, Katchel, Loren, Holmes, Ingrid, Rose, Stephen E., Baronet, Meghan C., Kryza, Thomas, Vito, Alyssa, Tieu, William, Kuan, Kevin, Griffiths, Matthew R., O’Mahoney, Eoin, Latter, Melissa, Gan, Chun Loo Loo and Wyld, David (2025). Phase Ib/IIa dose escalation and expansion study of [ 212 Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: TheraPb–phase I/II study. 2025 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 13-15 February 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.5_suppl.tps275 |
|
2025 Conference Publication Overall survival and quality of life with [ <sup>177</sup> Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901)Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M., Weickhardt, Andrew James, Lee, Sze Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian David, Sandhu, Shahneen, Zhang, Alison Yan, Hofman, Michael S., Thomas, Hayley, Martin, Andrew James, Davis, Ian D., Stockler, Martin R. and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). Overall survival and quality of life with [ 177 Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901). 2025 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 13-15 February 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.5_suppl.17 |
|
2025 Journal Article The global reading room: performing a ventilation-perfusion study in a patient with recent COVID-19Grady, Erin, Pattison, David A., Redman, Stewart and Satoh, Yoko (2025). The global reading room: performing a ventilation-perfusion study in a patient with recent COVID-19. American Journal of Roentgenology, 224 (2) e2431348, 1-2. doi: 10.2214/ajr.24.31348 |
|
2025 Journal Article A method for validating PET and SPECT cameras for quantitative clinical imaging trials using novel radionuclidesBailey, Dale L., Willowson, Kathy P., O’Keefe, Graeme, Goodman, Steven, Patford, Shaun, McGill, George, Pattison, David A. and Scott, Andrew M. (2025). A method for validating PET and SPECT cameras for quantitative clinical imaging trials using novel radionuclides. Journal of Nuclear Medicine, 66 (2), 315-322. doi: 10.2967/jnumed.124.268578 |
|
2025 Book Chapter Role of functional imaging in NENsChan, David L., Pattison, David A. and Kong, Grace (2025). Role of functional imaging in NENs. Neuroendocrine Neoplasia. (pp. 159-182) edited by Antongiulio Faggiano, Diego Ferone and Simron Singh. Cham, Switzerland: Springer. doi: 10.1007/978-3-031-83281-9_8 |
|
2024 Journal Article Intra-individual comparisons of [18F]fluorodeoxyglucose and prostate-specific membrane antigen positron emission tomography in prostate cancer patients across different disease states: new insights into disease heterogeneityMcGeorge, Stephen, Pattison, David A., Dhiantravan, Nattakorn, Thomas, Paul A., Yaxley, John W. and Roberts, Matthew J. (2024). Intra-individual comparisons of [18F]fluorodeoxyglucose and prostate-specific membrane antigen positron emission tomography in prostate cancer patients across different disease states: new insights into disease heterogeneity. Uro, 5 (1), 1-11. doi: 10.3390/uro5010001 |
|
2024 Journal Article Successful Localization of Recurrent MEN-1-Associated Hyperparathyroidism With 18F-Fluorocholine PET/CTWootton, Elizabeth, Wong, Clement, Love, Amanda and Pattison, David A. (2024). Successful Localization of Recurrent MEN-1-Associated Hyperparathyroidism With 18F-Fluorocholine PET/CT. JCEM Case Reports, 2 (12) luae222, 1-2. doi: 10.1210/jcemcr/luae222 |
|
2024 Journal Article Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 studyAzad, Arun A., Bressel, Mathias, Tan, Hsiang, Voskoboynik, Mark, Suder, Aneta, Weickhardt, Andrew J., Guminski, Alexander, Francis, Roslyn J., Saghebi, Javad, Dhiantravan, Nattakorn, Joshua, Anthony M., Emmett, Louise, Horvath, Lisa, Murphy, Declan G., Hsiao, Edward, Balakrishnar, Bavanthi, Lin, Peter, Redfern, Andrew, Macdonald, William, Ng, Siobhan, Lee, Sze-Ting, Pattison, David A., Nadebaum, David, Kirkwood, Ian D., Hofman, Michael S., Akhurst, T., Alipour, R., Au, L., Banks, P. ... on behalf of the UpFrontPSMA Study Team (2024). Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. The Lancet Oncology, 25 (10), 1267-1276. doi: 10.1016/s1470-2045(24)00440-6 |
|
2024 Journal Article The role of prostate-specific membrane antigen positron emission tomography/computed tomography in primary staging of selected renal tumours: initial experience in a multicentre cohortTariq, Arsalan, Pearce, Adam, Rhee, Handoo, Kyle, Samuel, Raveenthiran, Sheliyan, Pelecanos, Anita, Gan, Chun Loo, Goh, Jeffrey C., Wong, David, McBean, Rhiannon, Marsh, Phillip, Goodman, Steven, Dunglison, Nigel, Esler, Rachel, Navaratnam, Anojan, Yaxley, John W., Thomas, Paul, Pattison, David A. and Roberts, Matthew J. (2024). The role of prostate-specific membrane antigen positron emission tomography/computed tomography in primary staging of selected renal tumours: initial experience in a multicentre cohort. European Urology Focus, 10 (5), 770-778. doi: 10.1016/j.euf.2023.12.004 |
|
2024 Conference Publication A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC)Azad, A.A., Bressel, M., Tan, H., Voskoboynik, M., Suder, A., Weickhardt, A.J., Guminski, A., Francis, R.J., Saghebi, J., Dhiantravan, N., Joshua, A., Emmett, L., Murphy, D., Hsiao, E., Lee, S.T., Pattison, D.A., Nadebaum, D., Kirkwood, I.D. and Hofman, M.S. (2024). A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC). ESMO Congress 2024, Barcelona, Spain, 13-17 September 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2024.08.2309 |
